RU2016129069A - Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты - Google Patents
Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты Download PDFInfo
- Publication number
- RU2016129069A RU2016129069A RU2016129069A RU2016129069A RU2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A
- Authority
- RU
- Russia
- Prior art keywords
- alginic acid
- mannuronate
- contraceptive
- guluronate
- residues
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 239000000783 alginic acid Substances 0.000 title claims 11
- 235000010443 alginic acid Nutrition 0.000 title claims 11
- 229920000615 alginic acid Polymers 0.000 title claims 11
- 229960001126 alginic acid Drugs 0.000 title claims 11
- 150000004781 alginic acids Chemical class 0.000 title claims 11
- 239000000203 mixture Substances 0.000 title claims 9
- 150000001875 compounds Chemical class 0.000 title claims 5
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000003377 anti-microbal effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims 6
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims 5
- 230000000844 anti-bacterial effect Effects 0.000 claims 5
- 239000003433 contraceptive agent Substances 0.000 claims 5
- 230000002254 contraceptive effect Effects 0.000 claims 5
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims 4
- 239000000227 bioadhesive Substances 0.000 claims 4
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 125000005614 guluronate group Chemical group 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
- A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/065—Condom-like devices worn by females
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Способ предотвращения зачатия или снижения риска распространения заболеваний, передающихся половым путем, включающий местное введение контрацептивной бактерицидной композиции, содержащей около 1-10% альгиновой кислоты, около 1-10% биоадгезивного соединения и около 1-10% L-молочной кислоты;
при этом альгиновая кислота имеет соотношение остатков маннуроната : гулуроната в дипазоне от 0,25 до 2,0, и композиция находится в нематричном состоянии, когда не контактирует с эякулятом, и в матричном состоянии, когда контактирует с эякулятом.
2. Способ по п. 1, в котором альгиновая кислота имеет среднюю молекулярную массу от около 20000 до около 400000.
3. Способ по п. 1, в котором альгиновая кислота имеет среднюю молекулярную массу от около 75000 до около 375000.
4. Способ по п. 1, в котором альгиновая кислота имеет молекулярную массу от 100000 до 200000.
5. Способ по п. 1, в котором соотношение остатков маннуроната:гулуроната составляет от 0,2 до 0,45.
6. Способ по п. 5, в котором соотношение остатков маннуроната:гулуроната составляет от 0,3 до 0,45.
7. Способ по п. 6, в котором соотношение остатков маннуроната:гулуроната составляет от 0,35 до 0,45.
8. Способ по п. 1, в котором контрацептивная бактерицидная композиция содержит около 3-5% альгиновой кислоты, около 2,5-6% биоадгезивного соединения и около 1-7% L-молочной кислоты.
9. Способ по любому из пп. 1-8, в котором биоадгезивное соединение выбрано из группы, состоящей из: ксантановой камеди, альгиновой кислоты, гидроксипропилцеллюлозы, гидроксипропилметилцеллюлозы, натрий-карбоксиметалцеллюлозы, хитозана, поликарбофила и карбопола.
10. Способ по любому из пп. 1-8, в котором контрацептивная бактерицидная композиция имеет рН между около 3 и около 4.
11. Способ по любому из пп. 1-8, в котором контрацептивная бактерицидная композиция имеет рН между около 3,5 и около 4,5.
12. Способ предотвращения зачатия или снижения риска распространения заболеваний, передающихся половым путем, включающий местное введение контрацептивной бактерицидной композиции, содержащей около 1-10% альгиновой кислоты, около 1-10% биоадгезивного соединения и около 1-10% L-молочной кислоты, при этом альгиновая кислота имеет соотношение остатков маннуроната:гулуроната в дипазоне от 0,2 до 0,4.
13. Способ по п. 12, в котором альгиновая кислота имеет молекулярную массу от 20000 до 400000.
14. Способ по любому из пп. 1-8, 12-13, в котором композиция дополнительно содержит фармацевтически приемлемый носитель.
15. Способ по п. 14, в котором композиция дополнительно содержит фармацевтически приемлемый носитель на водной основе.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918445P | 2013-12-19 | 2013-12-19 | |
| US61/918,445 | 2013-12-19 | ||
| PCT/US2014/071664 WO2015095793A1 (en) | 2013-12-19 | 2014-12-19 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016129069A true RU2016129069A (ru) | 2018-01-23 |
| RU2691950C1 RU2691950C1 (ru) | 2019-06-19 |
Family
ID=53403777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016129069A RU2691950C1 (ru) | 2013-12-19 | 2014-12-19 | Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11337989B2 (ru) |
| EP (2) | EP3082826B1 (ru) |
| JP (3) | JP2017501227A (ru) |
| KR (1) | KR102407408B1 (ru) |
| CN (2) | CN106029078A (ru) |
| AU (2) | AU2014368971B2 (ru) |
| BR (1) | BR112016014506B1 (ru) |
| DK (1) | DK3082826T3 (ru) |
| ES (1) | ES2790703T3 (ru) |
| IL (1) | IL246146B2 (ru) |
| MX (2) | MX2016008023A (ru) |
| NZ (1) | NZ722215A (ru) |
| RU (1) | RU2691950C1 (ru) |
| WO (1) | WO2015095793A1 (ru) |
| ZA (1) | ZA201604862B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013187984A1 (en) | 2012-06-13 | 2013-12-19 | Evofem, Inc. | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| NZ722215A (en) | 2013-12-19 | 2019-02-22 | Evofem Inc | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
| DE102017110168A1 (de) | 2016-05-25 | 2017-11-30 | Samsung Electronics Co., Ltd. | Elektronische Vorrichtung mit NFC-Antenne |
| US20190209502A1 (en) * | 2016-09-12 | 2019-07-11 | Evofem, Inc. | Combination gel for sexually transmitted infections |
| AU2017338748A1 (en) * | 2016-10-04 | 2019-05-02 | Evofem Inc. | Method of treatment and prevention of bacterial vaginosis |
| WO2023076968A1 (en) * | 2021-10-28 | 2023-05-04 | Evofem, Inc. | Rapidly dissolving vaginal film with contraceptive action and sexually transmitted infection prevention |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1213323B (it) | 1986-08-07 | 1989-12-20 | Crinos Industria Farmaco | Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida |
| US4999342A (en) | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
| JP3202365B2 (ja) * | 1992-12-04 | 2001-08-27 | 株式会社紀文フードケミファ | オリゴマンヌロン酸を重合度によって分離する方法 |
| US5592949A (en) | 1994-06-29 | 1997-01-14 | Moench; Thomas R. | Device for acidic buffering and method for inactivation of pathogens |
| US5667492A (en) | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
| FR2728464B1 (fr) | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
| US6093394A (en) | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
| WO2001038284A1 (en) | 1999-11-24 | 2001-05-31 | Cargill Dow Llc | Improved lactic acid processing; methods; arrangements; and, products |
| PL202918B1 (pl) * | 2000-03-07 | 2009-08-31 | Rush Presbyterian St Luke | Przeciwbakteryjna i antykoncepcyjna kompozycja oraz jej zastosowanie |
| JP2009102407A (ja) * | 2001-03-08 | 2009-05-14 | Rohto Pharmaceut Co Ltd | Ｇリッチなアルギン酸含有組成物 |
| US20020177624A1 (en) | 2001-03-16 | 2002-11-28 | Calvin Hanna | Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis |
| ITMI20010913A1 (it) | 2001-05-04 | 2002-11-04 | Univ Pavia | Composizioni a rilascio controllato di acido lattico a livello vaginale |
| EP1399151A4 (en) * | 2001-06-11 | 2004-08-04 | Merck & Co Inc | METHOD FOR TREATING INFLAMMABLE DISEASES BY ADMINISTRATING A PPAR DELTA AGONIST |
| US20130150810A1 (en) | 2002-04-30 | 2013-06-13 | The Population Council, Inc. | Intravaginal ring for the delivery of unique combinations of antimicrobial compositions |
| WO2004011032A1 (ja) * | 2002-07-26 | 2004-02-05 | Mikasa Seiyaku Co., Ltd. | 外用剤 |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| DK1635847T3 (da) | 2003-06-13 | 2019-10-28 | Idh Holding Aps | Behandling af symptomer forbundet med bakteriel vaginose |
| US20050272700A1 (en) | 2004-05-10 | 2005-12-08 | Servet Buyuktimkin | Topical treatment and prevention of human papilloma virus (HPV) infection |
| RU2257197C1 (ru) * | 2004-05-12 | 2005-07-27 | Дулькис Мария Дмитриевна | Вагинальные суппозитории, обладающие контрацептивным действием |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| WO2008056786A1 (fr) * | 2006-11-10 | 2008-05-15 | Rohto Pharmaceutical Co., Ltd. | Composition pour application cutanée ou par voie muqueuse |
| US7659259B2 (en) * | 2006-12-21 | 2010-02-09 | Bausch & Lomb Incorporated | Method of treating inflammation of the eye |
| RU2459620C2 (ru) | 2007-03-30 | 2012-08-27 | Лаккуре Аб | Применение олигомеров молочной кислоты в лечении гинекологических расстройств |
| EP2146698A2 (en) | 2007-05-24 | 2010-01-27 | New York Blood Center, Inc. | Rapidly dispersible vaginal tablet that provides a bioadhesive gel |
| TW200927141A (en) | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
| MX2010011244A (es) | 2008-04-16 | 2010-11-09 | Cipla Ltd | Combinaciones topicas las cuales comprenden una agente antimicotico y un agente antiviral. |
| WO2009155118A1 (en) * | 2008-05-30 | 2009-12-23 | Reprotect, Inc. | Compositions and methods for inactivation of pathogens at genital tract surfaces |
| EP2130531A1 (en) | 2008-06-04 | 2009-12-09 | Rolf Kullgren AB | Vaginal suppository comprising lactic acid |
| WO2010142761A1 (en) | 2009-06-10 | 2010-12-16 | Ultimorphix Technologies B.V. | The succinate of tenofovir disoproxil |
| MX2013012745A (es) * | 2011-05-02 | 2014-12-05 | Aptalis Pharmatech Inc | Composiciones en forma de comprmido de disolución rápida para administración vaginal. |
| BR112013033759B1 (pt) | 2011-06-28 | 2021-05-25 | Chemo Research Sl | forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol |
| WO2013187984A1 (en) | 2012-06-13 | 2013-12-19 | Evofem, Inc. | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| WO2015027071A1 (en) | 2013-08-21 | 2015-02-26 | Georgia Regents Research Institute, Inc. | Gpr81 agonists and methods thereof for promoting production of secretory iga |
| NZ722215A (en) | 2013-12-19 | 2019-02-22 | Evofem Inc | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
| US9801839B2 (en) | 2014-02-28 | 2017-10-31 | Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd | Therapeutic method |
-
2014
- 2014-12-19 NZ NZ722215A patent/NZ722215A/en unknown
- 2014-12-19 AU AU2014368971A patent/AU2014368971B2/en active Active
- 2014-12-19 RU RU2016129069A patent/RU2691950C1/ru active
- 2014-12-19 US US15/106,755 patent/US11337989B2/en active Active
- 2014-12-19 BR BR112016014506-2A patent/BR112016014506B1/pt active IP Right Grant
- 2014-12-19 EP EP14871611.1A patent/EP3082826B1/en active Active
- 2014-12-19 KR KR1020167019494A patent/KR102407408B1/ko active Active
- 2014-12-19 MX MX2016008023A patent/MX2016008023A/es unknown
- 2014-12-19 DK DK14871611.1T patent/DK3082826T3/da active
- 2014-12-19 EP EP20161479.9A patent/EP3735966A1/en not_active Withdrawn
- 2014-12-19 JP JP2016560871A patent/JP2017501227A/ja active Pending
- 2014-12-19 CN CN201480075975.9A patent/CN106029078A/zh active Pending
- 2014-12-19 IL IL246146A patent/IL246146B2/en unknown
- 2014-12-19 ES ES14871611T patent/ES2790703T3/es active Active
- 2014-12-19 WO PCT/US2014/071664 patent/WO2015095793A1/en not_active Ceased
- 2014-12-19 CN CN202210078304.4A patent/CN114452298A/zh active Pending
-
2016
- 2016-06-17 MX MX2021001742A patent/MX2021001742A/es unknown
- 2016-07-14 ZA ZA2016/04862A patent/ZA201604862B/en unknown
-
2020
- 2020-03-31 JP JP2020063444A patent/JP2020125298A/ja active Pending
- 2020-04-29 AU AU2020202835A patent/AU2020202835B2/en active Active
-
2022
- 2022-02-07 JP JP2022017393A patent/JP2022070924A/ja active Pending
- 2022-04-19 US US17/724,378 patent/US20220241301A1/en not_active Abandoned
-
2024
- 2024-01-08 US US18/407,371 patent/US20240299426A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL246146B1 (en) | 2023-11-01 |
| MX2021001742A (es) | 2021-04-19 |
| JP2022070924A (ja) | 2022-05-13 |
| KR102407408B1 (ko) | 2022-06-10 |
| EP3082826A4 (en) | 2017-08-23 |
| IL246146A0 (en) | 2016-07-31 |
| BR112016014506A2 (pt) | 2017-10-31 |
| US11337989B2 (en) | 2022-05-24 |
| CN114452298A (zh) | 2022-05-10 |
| JP2017501227A (ja) | 2017-01-12 |
| ZA201604862B (en) | 2017-08-30 |
| RU2691950C1 (ru) | 2019-06-19 |
| AU2020202835A1 (en) | 2020-05-21 |
| ES2790703T3 (es) | 2020-10-28 |
| IL246146B2 (en) | 2024-03-01 |
| DK3082826T3 (da) | 2020-05-04 |
| KR20160103036A (ko) | 2016-08-31 |
| JP2020125298A (ja) | 2020-08-20 |
| AU2014368971A1 (en) | 2016-07-28 |
| US20160354394A1 (en) | 2016-12-08 |
| EP3735966A1 (en) | 2020-11-11 |
| BR112016014506B1 (pt) | 2022-06-28 |
| US20240299426A1 (en) | 2024-09-12 |
| AU2014368971B2 (en) | 2020-02-06 |
| EP3082826A1 (en) | 2016-10-26 |
| AU2020202835B2 (en) | 2021-12-02 |
| WO2015095793A1 (en) | 2015-06-25 |
| EP3082826B1 (en) | 2020-03-11 |
| NZ722215A (en) | 2019-02-22 |
| MX2016008023A (es) | 2017-01-13 |
| US20220241301A1 (en) | 2022-08-04 |
| CN106029078A (zh) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016129069A (ru) | Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| UA105766C2 (ru) | Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин | |
| BR112012024683A2 (pt) | preparado sólido facilmente dosável | |
| WO2014186742A3 (en) | Anhydrous hydrogel composition | |
| RU2011138101A (ru) | Фармацевтическая композиция, проявляющая противовоспалительные свойства | |
| JP2016503058A5 (ru) | ||
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| EA201690810A1 (ru) | Мягкие пастилки, содержащие экстракт куркумы | |
| WO2011070318A3 (en) | Topical formulation | |
| PH12021550014A1 (en) | Substituted thiophenecarboxamides and analogues as antibacterials agent | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| JP2017501227A5 (ru) | ||
| FI3666258T3 (fi) | Menetelmä prader-willin oireyhtymän hoitamiseksi | |
| RU2016131211A (ru) | Комбинированный лекарственный препарат для профилактики инфекций, передающихся половым путём | |
| AR075274A1 (es) | Agente de tratamiento de semillas y metodo para proteger una planta | |
| JP6646390B2 (ja) | 外用組成物 | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| JP2015528515A5 (ru) | ||
| JP2019529572A5 (ru) | ||
| UA118581C2 (uk) | Зволожувальні агенти | |
| JP2019504843A5 (ru) | ||
| WO2014006635A3 (en) | Solid oral compositions of silodosin | |
| WO2014007549A3 (ko) | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 | |
| JO3464B1 (ar) | التركيبات الخاصة بمركبات التياكوميسين |